In this issue:
Sofosbuvir + ribavirin in difficult-to-treat HCV
Faldaprevir + deleobuvir in HCV GT-1
Triple therapy not advised in HCV-cirrhosis
Adjuvant IFN after curative treatment in HCC
Predicting PEG-IFN response in HBeAg-positive CHB
Danoprevir + PEG-IFN-α-2a + RBV in HCV GT-1
A multidisciplinary support programme increases SVR
HCV: a significant concern in detained populations
Please login below to download this issue (PDF)